Dual Active Release Uniformity
Each tablet contains Clonazepam 0.5 mg and Melatonin 5 mg with precision content uniformity and consistent dissolution kinetics complying with Indian Pharmacopoeia standards.
DELOTRIL-PLUS-5 is an innovative dual-action neuro-hypnotic tablet combining Clonazepam IP 0.5 mg with Melatonin 5 mg by Blessme, Dellwich Lifescience LLP. Formulated to restore natural sleep architecture in patients suffering from anxiety-induced insomnia, delayed sleep phase syndrome, and nocturnal panic attacks without suppressing physiological deep sleep stages.

Detailed pharmaceutical specifications, active API monograph compliance, circadian sleep architecture restoration, and blister packaging details for DELOTRIL-PLUS-5.
DELOTRIL-PLUS-5 pairs 5 mg of the physiological sleep hormone Melatonin with 0.5 mg of the high-potency anxiolytic Clonazepam. It delivers physiological sleep onset while calming nocturnal anxiety and autonomic arousal.
In-depth pharmacological evaluation of Clonazepam IP 0.5 mg + Melatonin 5 mg tablets, marketed as DELOTRIL-PLUS-5 by Blessme (Dellwich Lifescience LLP). Covers circadian rhythm pharmacology, sleep architecture restoration, and pharmaceutical supply across India.
DELOTRIL-PLUS-5 is an advanced sleep-regulating tablet combining a circadian chronobiotic agent with an inhibitory GABAergic anxiolytic. In patients with severe anxiety, elevated nocturnal sympathetic tone and hypercortisolemia suppress pineal melatonin secretion, producing intractable sleep initiation insomnia.
When somnologists and psychiatrists search for Clonazepam Melatonin tablet or medicine for anxiety-induced insomnia and nocturnal panic, they look for dual-target formulations that do not distort natural REM and slow-wave sleep. DELOTRIL-PLUS-5 meets these rigorous requirements through automated clean-room manufacturing under WHO-GMP compliance.
Approved neurological and psychiatric indications for DELOTRIL-PLUS-5 include:
Melatonin 5 mg acts as a high-affinity agonist at MT1 and MT2 G-protein coupled receptors located in the suprachiasmatic nucleus (SCN) of the anterior hypothalamus. MT1 receptor activation attenuates SCN neuronal firing, promoting hypothermia and initiating the physiological sleep cascade, while MT2 activation facilitates circadian phase shifting.
Concurrently, Clonazepam 0.5 mg binds stereospecifically to GABAA receptor complexes in the thalamic reticular nucleus and limbic system. By potentiating chloride channel conductance, it stabilizes cortical hyperarousal, quiets racing thoughts, and suppresses nocturnal panic awakenings. Together, they restore peaceful, restorative sleep architecture throughout the night.
Clinical benefits of DELOTRIL-PLUS-5 over classical Z-drugs and sedatives:
DELOTRIL-PLUS-5 must be taken strictly in accordance with medical advice:
DELOTRIL-PLUS-5 contains Clonazepam, which carries potential for tolerance and habit formation with prolonged therapy. Strictly avoid alcohol or concurrent CNS depressant medications. Dispensed strictly against a valid medical prescription.
DELOTRIL-PLUS-5 is manufactured in WHO-GMP certified facilities adhering to Schedule M protocols, ensuring micro-blend homogeneity and maximum packaging stability.
Each tablet contains Clonazepam 0.5 mg and Melatonin 5 mg with precision content uniformity and consistent dissolution kinetics complying with Indian Pharmacopoeia standards.
Sealed in high-barrier blister strips specially coated to protect photosensitive Melatonin and hygroscopic excipients from environmental breakdown across tropical conditions.
Every batch is backed by authenticated Certificates of Analysis (COA), disintegration profiles, assay validation data, and Material Safety Data Sheets for hospital audits.
Produced in state-of-the-art accredited manufacturing units in Gujarat adhering to automated compression, online check-weighing, and Good Laboratory Practices (GLP).
Prescribing guidance, contraindications, and drug interactions for Clonazepam 0.5 mg + Melatonin 5 mg tablets.
DELOTRIL-PLUS-5 is a Schedule H prescription drug. Not for OTC sale. Do not consume alcohol during therapy. Exercise caution when driving or operating machinery the following morning.
Approved neurological and psychiatric indications for DELOTRIL-PLUS-5:
Key contraindications and monitoring requirements:
Dellwich Lifescience LLP is an established pharmaceutical company based in Science City, Ahmedabad, Gujarat, dedicated to advanced formulation technology, uncompromising quality assurance, and ethical healthcare supply. Through our specialized neurology division, Blessme, we manufacture and market superior neuro-psychiatric treatments, including DELOTRIL-PLUS-5 (Clonazepam 0.5 mg + Melatonin 5 mg Tablets).
We support PCD pharma franchise partners, hospital supply chains, and contract manufacturing clients across India with guaranteed supply security, validated product dossiers, and prompt dispatch.
Whether you are seeking DELOTRIL-PLUS-5 for district monopoly PCD franchise distribution, third-party contract manufacturing, or hospital bulk procurement, Dellwich Lifescience LLP delivers dependable supply and competitive trade margins.
Secure district-level monopoly marketing rights for DELOTRIL-PLUS-5 and the Blessme neuropsychiatry range with visual aids, product glossaries, and promotional input support.
Turnkey manufacturing solutions for pharmaceutical marketing companies with flexible batch runs, rapid production turnaround, and full regulatory dossier support from Ahmedabad.
Direct bulk pharmaceutical supply agreements for multispecialty hospital chains, psychiatric nursing homes, and institutional medical tenders with prompt pan-India logistics.
When sourcing Clonazepam Melatonin tablets in India, DELOTRIL-PLUS-5 by Blessme provides exceptional clinical efficacy, reliable blister packaging, and comprehensive B2B franchise support.
Manufactured in accredited facilities using IP grade APIs, ensuring exact active content uniformity and fast disintegration.
Tamper-evident, moisture-resistant blister strips protect tablets from ambient humidity and light degradation.
Direct factory dispatch with GST invoicing, verified batch COA, and dependable logistics coverage across all Indian states.
Exclusive district-level franchise rights for DELOTRIL-PLUS-5 and the Blessme portfolio with promotional visual aids.
Certificates of Analysis (COA), stability testing data, and MSDS readily available for institutional audits and tenders.
Direct access to Dellwich Lifescience product specialists for quick quotes, customized bulk orders, and customer assistance.
Authoritative answers to clinical, commercial, dosage, and regulatory questions regarding Clonazepam + Melatonin tablets.
DELOTRIL-PLUS-5 is an oral prescription tablet from the Blessme division of Dellwich Lifescience. It combines Clonazepam IP 0.5 mg (a potent anxiolytic benzodiazepine) with Melatonin 5 mg (a natural chronobiotic hormone), specifically engineered to treat sleep disturbances comorbid with severe anxiety.
Standard sedative hypnotics (such as Zolpidem or Zopiclone) solely induce sedation without addressing underlying anxiety or circadian rhythm disruption. DELOTRIL-PLUS-5 restores the physiological circadian signal via Melatonin while simultaneously relieving anxiety and muscle tension via Clonazepam, leading to higher sleep quality.
DELOTRIL-PLUS-5 should be taken once daily at bedtime, approximately 30 to 60 minutes before intending to sleep, strictly as prescribed by a qualified physician.
Melatonin is cleared rapidly from the body and does not cause residual grogginess. However, Clonazepam has an elimination half-life of 30 to 40 hours. In initial days of therapy, some patients may experience mild daytime drowsiness. Patients should ensure at least 7 to 8 hours of dedicated sleep time.
Melatonin carries zero dependence risk. However, Clonazepam has potential for tolerance and dependence with long-term continuous use. For this reason, DELOTRIL-PLUS-5 is recommended for short-to-medium term therapy under physician supervision.
Following extended continuous usage, treatment should be tapered gradually under medical direction rather than abruptly discontinued, to avoid rebound insomnia and withdrawal anxiety.
No. Alcohol interacts dangerously with Clonazepam, intensifying central nervous system depression, leading to severe drowsiness, respiratory suppression, and impaired coordination.
Elderly patients are more sensitive to benzodiazepines and have higher risks of nocturnal ataxia, confusion, and falls. In elderly individuals, doctors typically start with lower initial doses or evaluate risk-benefit carefully.
Yes. Under medical supervision, DELOTRIL-PLUS-5 can help reset disrupted circadian rhythms while reducing travel-induced anxiety and insomnia.
DELOTRIL-PLUS-5 is packed in 10x10 blister strips manufactured with high-barrier protective foils to prevent photolytic and moisture breakdown of Melatonin and Clonazepam.
DELOTRIL-PLUS-5 combines Clonazepam with Melatonin for bedtime use to treat sleep architecture disorders and nighttime panic. DELOTRIL-PRO-0.5 combines Clonazepam with Propranolol (a beta-blocker) for daytime somatic panic attacks and palpitations.
Interested distributors can submit an enquiry via the form below or message our franchise support team on WhatsApp at +91 99099 31992 for territory availability and price quotations.
Yes. Dellwich Lifescience provides end-to-end third-party manufacturing for Clonazepam + Melatonin tablets with customized branding, regulatory dossiers, and prompt batch deliveries.
Dellwich Lifescience LLP is headquartered on Science City Road, Ahmedabad, Gujarat, India, with delivery operations spanning pan-India healthcare networks.
Connect directly with Dellwich Lifescience LLP for trade pricing, district monopoly PCD rights, third-party manufacturing, or institutional hospital tender supplies.
Get wholesale pricing, PCD franchise monopoly rights, and technical documentation for Clonazepam + Melatonin Sleep Architecture Tablets.